SCHEMBL4309552

SCHEMBL4309552

CC(C)C(=O)Nc1ccccc1/C=C/c1n[nH]c2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.49
MDM4 O15151 2/20 0.43
TP53 P04637 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
AURKA O14965 3/20 0.41
CHEK1 O14757 2/20 0.41
FLT3 P36888 2/20 0.41
BMPR1B O00238 1/20 0.41
PLK4 O00444 1/20 0.41
STK25 O00506 1/20 0.41
CIT O14578 1/20 0.41
RIOK3 O14730 1/20 0.41
IKBKB O14920 1/20 0.41
GAK O14976 1/20 0.41
DCLK1 O15075 1/20 0.41
CHUK O15111 1/20 0.41
MUSK O15146 1/20 0.41
EPHB6 O15197 1/20 0.41
PDPK1 O15530 1/20 0.41
MAP3K13 O43283 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27711635 1.00 KDR (0.49) KDRMDM4TP53L3MBTL1AURKA
SCHEMBL4317521 0.86 FGFR1 (0.48) KDRAURKACHEK1FLT3BMPR1B
SCHEMBL4317526 0.86 FGFR1 (0.48) KDRAURKACHEK1FLT3BMPR1B
SCHEMBL4314953 0.86 KDR (0.41) KDRL3MBTL1AURKACHEK1FLT3
SCHEMBL4314947 0.86 KDR (0.41) KDRL3MBTL1AURKACHEK1FLT3
SCHEMBL4322819 0.84 GAA (0.44) KDRAURKACHEK1FLT3BMPR1B
SCHEMBL4322828 0.84 GAA (0.44) KDRAURKACHEK1FLT3BMPR1B
SCHEMBL4309474 0.83 KDR (0.51) KDRAURKACHEK1FLT3PLK4
SCHEMBL4309480 0.83 KDR (0.51) KDRAURKACHEK1FLT3PLK4
SCHEMBL4315179 0.82 KDR (0.59) KDRCHEK1JAK2LCKFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 KDR 75/4885MDM4 4259/4885TP53 3470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.